English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

With their ground-breaking clinical success, immune checkpoint inhibitors (ICIs) have opened a new chapter in cancer treatment; however, not all patients have a response to ICI treatment. Current approaches to maximizing the efficacy of ICI treatment include combining it with conventional cancer treatments and identifying biomarkers that accurately predict tumor responses to ICI agents. This mini-review introduces genomic determinants of ICI efficacy and directions for future immunogenomic studies in the era of checkpoint inhibition.

Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy